Navigation Links
Sirius Genomics Announces Appointment of Senior Director of Business Development

VANCOUVER, June 30 /PRNewswire/ - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced today that Kamran Alam has been appointed Senior Director of Business Development.

"Sirius Genomics is on track with our existing products and looking to grow our pipeline. Kam's extensive background in partnering with both global pharmaceutical and medical device companies as well as experience in building collaborations with academic and translational research centers will support our commercialization initiatives and product pipeline development," stated Chris Wagner, President and CEO of Sirius Genomics.

Mr. Alam has over 12 years experience in the biotech and medical device industry, during which time he has worked in several therapeutic areas in the roles of Business Development and Finance. Prior to joining Sirius Genomics, Mr. Alam held positions in business development at the Centre for Drug Research and Development, Angiotech Pharmaceuticals, and AnorMED Inc., and has successfully completed numerous and varied partnering deals, mergers and acquisitions, licensing transactions, and has executed extensive business development initiatives in the U.S., Europe and Asia.

Mr. Alam's professional experience also includes roles with PricewaterhouseCoopers LLP Chartered Accountants. A member of the Institute of Chartered Accountants of British Columbia, Mr. Alam holds an MBA Degree, specializing in International Business and Strategy, and a Bachelor of Science Degree, specializing in Cell Biology and Genetics.

About Sirius Genomics:

Sirius Genomics is a drug-enabling company that develops pharmacogenomic (PGx) diagnostics that lead to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The Company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable PGx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

SOURCE Sirius Genomics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
2. Sirius Genomics to Present at Invest Northwest Conference
3. Sirius Genomics Announces 2009 Board of Directors
4. Dr. Robert Lanza is Featured Guest on Deepak Chopras SIRIUS XM Stars Radio Show
5. Sirius Genomics Announces Change in Leadership
6. Learn Proven Practices to Measure, Align and Transform at SiriusDecisions Sales and Marketing Summit 2010
7. Industry Leaders from Blue Coat, Oracle, Polycom, Siemens and Taleo Headline SiriusDecisions Sales and Marketing Summit 2010
8. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
9. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
10. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
11. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
Post Your Comments:
(Date:10/11/2017)... NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic ... one eye at a time. So which eye do you rinse first if a dangerous ... have Plum Duo Eye Wash with its unique dual eye piece. , “Whether ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofilerâ„¢ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... CALIF. (PRWEB) , ... October 10, 2017 , ... San ... part of its corporate rebranding initiative announced today. The bold new look is ... reach, as the company moves into a significant growth period. , It will also ...
(Date:10/10/2017)... International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, ... security market and how smart safety and security products impact the competitive ... Parks Associates: Smart Home Devices: Main ... "The residential security market has experienced continued ...
Breaking Biology Technology:
(Date:5/23/2017)... May 23, 2017  Hunova, the first robotic gym for the rehabilitation ... officially launched in Genoa, Italy . The first 30 ... and the USA . The technology was developed and ... by the IIT spin-off Movendo Technology thanks to a 10 million euro ... Release, please click: ...
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
Breaking Biology News(10 mins):